Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring2021Vol. 13(1), pp. e12131–e12131
Citations Over TimeTop 10% of 2021 papers
Ashvini Keshavan, Henrietta Wellington, Zhongbo Chen, Ayesha Khatun, Miles Chapman, Melanie Hart, David M. Cash, William Coath, Thomas D. Parker, Sarah M. Buchanan, Sarah E Keuss, Matthew Harris, Heidi Murray‐Smith, Amanda Heslegrave, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott
Abstract
The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology.
Related Papers
- → Parental non-concordance with occlusion therapy(2000)101 cited
- → The Promise and Limits of Racial/Ethnic Concordance in Physician-Patient Interaction(2006)54 cited
- → How to Improve the Drafting of Health Profiles(2022)2 cited
- → Concordance with Medication and Older People(2007)
- A concordance to King Horn ; a concordance to Athelston ; a concordance to Gamelyn(1986)